CALA News and Press, Calithera Biosciences Inc. From 05/27/21

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced ...

Calithera Biosciences (CALA) and Antengene announce an exclusive, worldwide license agreement for the development and commercialization of CB-708 (ATG-037).CB-708 is Calithera's small molecule inhibitor of CD73, which generates adenosine that is highly immunosuppressive. It enh...

--CB-708 is an oral small molecule inhibitor of CD73 in preclinical development for oncology --Antengene is granted exclusive rights to develop and commercialize asset discovered and initially developed by Calithera SOUTH SAN FRANCISCO, Calif. and SHANGHAI, China, May 17, 2021...

The following slide deck was published by Calithera Biosciences, Inc. in conjunction with this event. For further details see: Calithera Biosciences Investor Presentation - Slideshow

Image source: The Motley Fool. Calithera Biosciences Inc (NASDAQ: CALA) Q1 2021 Earnings Call May 6, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Calithera Biosciences Inc (CALA) Q1 2021 Earnings Call Transcript ...

--$102.9 Million in Cash and Investments at March 31, 2021-- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on May 6, 2021-- SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology com...

SOUTH SAN FRANCISCO, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today ann...

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announce...

Shares of Calithera Biosciences Inc. (NASDAQ:CALA) traded at a new 52-week low today of $2.06. This new low was reached on above average trading volume as 1.8 million shares traded hands, while the average 30-day volume is approximately 841,000 shares. In the past 52 weeks, Calithera Bio...

Calithera Biosciences Inc. (NASDAQ:CALA) traded at a new 52-week low today of $2.08. So far today approximately 1.8 million shares have been exchanged, as compared to an average 30-day volume of 965,000 shares. In the past 52 weeks, Calithera Biosciences Inc. share prices are bracketed b...